Lurasidone vs Paliperidone (Invega)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Lurasidone

Marketed by Sumitomo Pharma and partners

Approved in Schizophreniasmall molecule
Reliable signal

NCT00549718 · Phase 3 · completed

The study randomized approximately 500 participants to lurasidone 40, 80, or 120 mg or placebo and used quadruple masking of participants, clinicians, investigators, and outcome assessors. Its clinical primary endpoint, change in total PANSS score over 6 weeks, favored lurasidone overall versus placebo and was statistically significant (p<0.05).

Reported efficacy

Mean change in Total PANSS Score From Baseline at Week 6: Change in PANSS total score at week 6 (prespecified primary analysis in the per-protocol set): -26.42±2.02 lurasidone vs -27.33±2.01 quetiapine XR (adjusted mean±SE); difference -0.91 (95% CI -6.35 to 4.53); lower limit above the -8.99 non-inferiority margin, met. The ITT set analysis also showed non-inferiority. (met)

Result source: NCT03465787

Paliperidone (Invega)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2027 · NCT04478838 (registry estimate)

Reported efficacy

Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)

Result source: NCT04072575

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLurasidonePaliperidone (Invega)
PANSS total, change-26.5 vs -10.3−16.2 vs placebo160 mg · wk 6 · n 121NCT00790192
24 other results
  • -19.2 vs -17 40mg · wk 6 · n 121 · Phase 3 · primary NCT00549718
  • -25.7 vs -16 40 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -18.6 vs -10.5 40 mg · wk 6 · n 108 · Phase 3 · primary NCT01911429
  • -17.9 vs -13.1 40 mg · wk 6 · n 145 · Phase 3 · primary NCT01614899
  • -6.1 vs -2.5 40 mg · wk 6 · n 125 · Phase 3 · primary NCT00711269
  • -20.5 vs -17 120mg · wk 6 · n 123 · Phase 3 · primary NCT00549718
  • -23.6 vs -16 120 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -23.4 vs -17 80mg · wk 6 · n 118 · Phase 3 · primary NCT00549718
  • -18.3 vs -10.5 80 mg · wk 6 · n 106 · Phase 3 · primary NCT01911429
  • -17.3 vs -13.1 80 mg · wk 6 · n 152 · Phase 3 · primary NCT01614899
  • -22.2 vs -10.3 80 mg · wk 6 · n 125 · Phase 3 · primary NCT00790192
  • -4.3 vs -2.5 80 mg · wk 6 · n 129 · Phase 3 · primary NCT00711269
  • -17.6 vs -14.5 20 mg · wk 6 · n 101 · Phase 3 · primary NCT01821378
  • -24.9 vs -14.5 80-160 mg · wk 6 · n 198 · Phase 3 · primary NCT01821378
  • -31.2 vs -34.9 wk 6 · n 194 · Phase 3 · primary NCT02002832
  • -21.7 vs -14.4 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -14.4 vs -14.4 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 8.3 vs 12.4 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -34.6 vs -25.7 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -14.1 vs -5.5 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -7.1 vs -12.3 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -7.2 vs -12.3 wk 6 · n 65 · Phase 2 · secondary NCT00044044
  • -13.6 vs -12.3 wk 6 · n 70 · Phase 2 · secondary NCT00044044
  • -26.4 vs -27.3 wk 6 · Phase 3 · primary NCT03465787
-9.8 vs -7.9−1.9 vs placebowk 6 · n 54NCT00518323
8 other results
  • -17.3 vs -7.9 wk 6 · n 48 · Phase 3 · primary NCT00518323
  • -13.8 vs -7.9 wk 6 · n 47 · Phase 3 · primary NCT00518323
  • -9.1 vs 3.8 wk 6 · n 134 · Phase 3 · primary NCT00396565
  • -19.3 vs -19.8 wk 8 · n 112 · Phase 3 · primary NCT01009047
  • -13.5 vs -16.6 wk 24 · n 234 · Phase 3 · secondary NCT00645099
  • -25.6 vs -26.8 wk 26 · n 112 · Phase 3 · secondary NCT01009047
  • -15 vs -11.7 6 mg · wk 6 · n 70 · Phase 4 · primary NCT00524043
  • -8.9 vs -11.7 1.5 mg · wk 6 · n 66 · Phase 4 · primary NCT00524043
CGI-S, change-1.1 vs -1−0.1 vs placebo40mg · wk 6 · n 122NCT00549718
20 other results
  • -1.5 vs -1.1 40 mg · wk 6 · n 119 · Phase 3 · secondary NCT00615433
  • -1.0 vs -0.5 40 mg · wk 6 · n 108 · Phase 3 · secondary NCT01911429
  • -0.9 vs -0.8 40 mg · wk 6 · n 140 · Phase 3 · secondary NCT01614899
  • -1.3 vs -0.7 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -1.7 vs -0.9 160 mg · wk 6 · n 121 · Phase 3 · secondary NCT00790192
  • -1.2 vs -1 120mg · wk 6 · n 124 · Phase 3 · secondary NCT00549718
  • -1.4 vs -1.1 120 mg · wk 6 · n 118 · Phase 3 · secondary NCT00615433
  • -1.4 vs -1 80mg · wk 6 · n 119 · Phase 3 · secondary NCT00549718
  • -0.9 vs -0.5 80 mg · wk 6 · n 106 · Phase 3 · secondary NCT01911429
  • -1.0 vs -0.8 80 mg · wk 6 · n 150 · Phase 3 · secondary NCT01614899
  • -1.5 vs -0.9 80 mg · wk 6 · n 125 · Phase 3 · secondary NCT00790192
  • -0.9 vs -0.7 20 mg · wk 6 · n 101 · Phase 3 · secondary NCT01821378
  • -1.3 vs -0.7 80-160 mg · wk 6 · n 198 · Phase 3 · secondary NCT01821378
  • -0.8 vs -0.7 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 0.4 vs 0.7 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -1.9 vs -1.6 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -0.6 vs -0.2 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -0.5 vs -0.7 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -0.4 vs -0.7 wk 6 · n 64 · Phase 2 · secondary NCT00044044
  • -0.8 vs -0.7 wk 6 · n 70 · Phase 2 · secondary NCT00044044
0 vs 0±0 vs placebowk 6 · n 54NCT00518323
7 other results
  • -1 vs 0 wk 6 · n 48 · Phase 3 · secondary NCT00518323
  • -1 vs 0 wk 6 · n 47 · Phase 3 · secondary NCT00518323
  • -0.4 vs 0.2 wk 6 · n 134 · Phase 3 · secondary NCT00396565
  • -1 vs -1 wk 8 · n 112 · Phase 3 · secondary NCT01009047
  • -1 vs -1 wk 26 · n 112 · Phase 3 · secondary NCT01009047
  • -0.5 vs -1 6 mg · wk 6 · n 70 · Phase 4 · secondary NCT00524043
  • 0 vs -1 1.5 mg · wk 6 · n 66 · Phase 4 · secondary NCT00524043
PANSS response—Not posted · NCT0114309076.8% vs 81.6%vs Aripiprazolewk 26 · n 112NCT01009047
1 other result
  • 67.9% vs 76.3% wk 8 · n 112 · Phase 3 · secondary NCT01009047
PSP, change—Not posted · NCT0114309017.1 vs 17.1vs Aripiprazolewk 26 · n 112NCT01009047
3 other results
  • 12.2 vs 12.2 wk 8 · n 112 · Phase 3 · secondary NCT01009047
  • 5.7 vs 1.6 6 mg · wk 6 · n 70 · Phase 4 · secondary NCT00524043
  • 2.9 vs 1.6 1.5 mg · wk 6 · n 66 · Phase 4 · secondary NCT00524043
Relapse (% of patients)20.9% vs 26.6%vs Quetiapinewk 52 · n 139NCT00789698—Not posted · NCT03485417

PANSS total, change

Lurasidone
-26.5 vs -10.3−16.2 vs placebo160 mg · wk 6 · n 121NCT00790192
24 other results
  • -19.2 vs -17 40mg · wk 6 · n 121 · Phase 3 · primary NCT00549718
  • -25.7 vs -16 40 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -18.6 vs -10.5 40 mg · wk 6 · n 108 · Phase 3 · primary NCT01911429
  • -17.9 vs -13.1 40 mg · wk 6 · n 145 · Phase 3 · primary NCT01614899
  • -6.1 vs -2.5 40 mg · wk 6 · n 125 · Phase 3 · primary NCT00711269
  • -20.5 vs -17 120mg · wk 6 · n 123 · Phase 3 · primary NCT00549718
  • -23.6 vs -16 120 mg · wk 6 · n 118 · Phase 3 · primary NCT00615433
  • -23.4 vs -17 80mg · wk 6 · n 118 · Phase 3 · primary NCT00549718
  • -18.3 vs -10.5 80 mg · wk 6 · n 106 · Phase 3 · primary NCT01911429
  • -17.3 vs -13.1 80 mg · wk 6 · n 152 · Phase 3 · primary NCT01614899
  • -22.2 vs -10.3 80 mg · wk 6 · n 125 · Phase 3 · primary NCT00790192
  • -4.3 vs -2.5 80 mg · wk 6 · n 129 · Phase 3 · primary NCT00711269
  • -17.6 vs -14.5 20 mg · wk 6 · n 101 · Phase 3 · primary NCT01821378
  • -24.9 vs -14.5 80-160 mg · wk 6 · n 198 · Phase 3 · primary NCT01821378
  • -31.2 vs -34.9 wk 6 · n 194 · Phase 3 · primary NCT02002832
  • -21.7 vs -14.4 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -14.4 vs -14.4 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 8.3 vs 12.4 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -34.6 vs -25.7 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -14.1 vs -5.5 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -7.1 vs -12.3 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -7.2 vs -12.3 wk 6 · n 65 · Phase 2 · secondary NCT00044044
  • -13.6 vs -12.3 wk 6 · n 70 · Phase 2 · secondary NCT00044044
  • -26.4 vs -27.3 wk 6 · Phase 3 · primary NCT03465787
Paliperidone (Invega)
-9.8 vs -7.9−1.9 vs placebowk 6 · n 54NCT00518323
8 other results
  • -17.3 vs -7.9 wk 6 · n 48 · Phase 3 · primary NCT00518323
  • -13.8 vs -7.9 wk 6 · n 47 · Phase 3 · primary NCT00518323
  • -9.1 vs 3.8 wk 6 · n 134 · Phase 3 · primary NCT00396565
  • -19.3 vs -19.8 wk 8 · n 112 · Phase 3 · primary NCT01009047
  • -13.5 vs -16.6 wk 24 · n 234 · Phase 3 · secondary NCT00645099
  • -25.6 vs -26.8 wk 26 · n 112 · Phase 3 · secondary NCT01009047
  • -15 vs -11.7 6 mg · wk 6 · n 70 · Phase 4 · primary NCT00524043
  • -8.9 vs -11.7 1.5 mg · wk 6 · n 66 · Phase 4 · primary NCT00524043

CGI-S, change

Lurasidone
-1.1 vs -1−0.1 vs placebo40mg · wk 6 · n 122NCT00549718
20 other results
  • -1.5 vs -1.1 40 mg · wk 6 · n 119 · Phase 3 · secondary NCT00615433
  • -1.0 vs -0.5 40 mg · wk 6 · n 108 · Phase 3 · secondary NCT01911429
  • -0.9 vs -0.8 40 mg · wk 6 · n 140 · Phase 3 · secondary NCT01614899
  • -1.3 vs -0.7 160 mg · wk 6 · n 43 · Phase 3 · secondary NCT01821378
  • -1.7 vs -0.9 160 mg · wk 6 · n 121 · Phase 3 · secondary NCT00790192
  • -1.2 vs -1 120mg · wk 6 · n 124 · Phase 3 · secondary NCT00549718
  • -1.4 vs -1.1 120 mg · wk 6 · n 118 · Phase 3 · secondary NCT00615433
  • -1.4 vs -1 80mg · wk 6 · n 119 · Phase 3 · secondary NCT00549718
  • -0.9 vs -0.5 80 mg · wk 6 · n 106 · Phase 3 · secondary NCT01911429
  • -1.0 vs -0.8 80 mg · wk 6 · n 150 · Phase 3 · secondary NCT01614899
  • -1.5 vs -0.9 80 mg · wk 6 · n 125 · Phase 3 · secondary NCT00790192
  • -0.9 vs -0.7 20 mg · wk 6 · n 101 · Phase 3 · secondary NCT01821378
  • -1.3 vs -0.7 80-160 mg · wk 6 · n 198 · Phase 3 · secondary NCT01821378
  • -0.8 vs -0.7 80 mg · wk 6 · n 52 · Phase 3 · secondary NCT01821378
  • 0.4 vs 0.7 wk 28 · n 144 · Phase 3 · secondary NCT01435928
  • -1.9 vs -1.6 wk 52 · n 132 · Phase 3 · secondary NCT00789698
  • -0.6 vs -0.2 80 mg · wk 6 · n 90 · Phase 2 · secondary NCT00088634
  • -0.5 vs -0.7 wk 6 · n 71 · Phase 2 · secondary NCT00044044
  • -0.4 vs -0.7 wk 6 · n 64 · Phase 2 · secondary NCT00044044
  • -0.8 vs -0.7 wk 6 · n 70 · Phase 2 · secondary NCT00044044
Paliperidone (Invega)
0 vs 0±0 vs placebowk 6 · n 54NCT00518323
7 other results
  • -1 vs 0 wk 6 · n 48 · Phase 3 · secondary NCT00518323
  • -1 vs 0 wk 6 · n 47 · Phase 3 · secondary NCT00518323
  • -0.4 vs 0.2 wk 6 · n 134 · Phase 3 · secondary NCT00396565
  • -1 vs -1 wk 8 · n 112 · Phase 3 · secondary NCT01009047
  • -1 vs -1 wk 26 · n 112 · Phase 3 · secondary NCT01009047
  • -0.5 vs -1 6 mg · wk 6 · n 70 · Phase 4 · secondary NCT00524043
  • 0 vs -1 1.5 mg · wk 6 · n 66 · Phase 4 · secondary NCT00524043

PANSS response

Lurasidone
—Not posted · NCT01143090
Paliperidone (Invega)
76.8% vs 81.6%vs Aripiprazolewk 26 · n 112NCT01009047
1 other result
  • 67.9% vs 76.3% wk 8 · n 112 · Phase 3 · secondary NCT01009047

PSP, change

Lurasidone
—Not posted · NCT01143090
Paliperidone (Invega)
17.1 vs 17.1vs Aripiprazolewk 26 · n 112NCT01009047
3 other results
  • 12.2 vs 12.2 wk 8 · n 112 · Phase 3 · secondary NCT01009047
  • 5.7 vs 1.6 6 mg · wk 6 · n 70 · Phase 4 · secondary NCT00524043
  • 2.9 vs 1.6 1.5 mg · wk 6 · n 66 · Phase 4 · secondary NCT00524043

Relapse (% of patients)

Lurasidone
20.9% vs 26.6%vs Quetiapinewk 52 · n 139NCT00789698
Paliperidone (Invega)
—Not posted · NCT03485417
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety

Coverage. Lurasidone: 12 of 12 rows · Paliperidone (Invega): 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLurasidone
Rows use multiple source trials
Paliperidone (Invega)
Rows use multiple source trials
CGAS
absolute change · score
11.3 vs 7.5 placebo score @ 6wk40 mga,b,c
NCT01911429 · Phase 3 · registry result, not featured evidence
show 1 more dose
11.9 vs 7.5 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
8.6 vs 5 placebo score @ 6wka,b,c
NCT00518323 · Phase 3 · registry result, not featured evidence
show 2 more doses
4.4 vs 5 placebo score @ 6wk
NCT00518323 · Phase 3 · registry result, not featured evidence
13.1 vs 5 placebo score @ 6wk
NCT00518323 · Phase 3 · registry result, not featured evidence
CGI-S
absolute change · score
No placebo or comparator arm
-0.96 score @ 6wk160 mga,d,b,c
NCT01821378 · Phase 3 · registry result, not featured evidence
show 1 more dose
-0.61 score @ 6wk80 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
-0.8 score @ 6wka,d,b,c
NCT00535132 · Phase 4 · registry result, not featured evidence
show 1 more dose
-0.8 score @ 6wk
NCT00535132 · Phase 4 · registry result, not featured evidence
PANSS General Psychopathology
absolute change · score
-8.1 vs -5.3 placebo score @ 6wk40 mga,b,c
NCT01911429 · Phase 3 · registry result, not featured evidence
show 1 more dose
-8.1 vs -5.3 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
-4.1 vs 2.2 placebo score @ 6wkb,c
NCT00396565 · Phase 3 · registry result, not featured evidence
PANSS Negative Subscale
absolute change · score
-3.9 vs -2.9 placebo score @ 6wk40 mga,b,c
NCT01614899 · Phase 3 · registry result, not featured evidence
show 1 more dose
-3.4 vs -2.9 placebo score @ 6wk80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
-2.4 vs 0 placebo score @ 6wkb,c
NCT00396565 · Phase 3 · registry result, not featured evidence
PANSS Positive Subscale
absolute change · score
-5.4 vs -4.2 placebo score @ 6wk40 mga,b,c
NCT01614899 · Phase 3 · registry result, not featured evidence
show 1 more dose
-6.2 vs -4.2 placebo score @ 6wk80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
-2.6 vs 1.6 placebo score @ 6wkb,c
NCT00396565 · Phase 3 · registry result, not featured evidence
PANSS Positive Subscale
absolute change · score
No placebo or comparator arm
24.2 score @ 24wkb,c,e
NCT01569659 · Phase 4 · registry result, not featured evidence
11.16 score @ 26wkb,c,e
NCT01724359 · Phase 4 · registry result, not featured evidence
2 other source trials
-7.17 score @ 26wk
NCT01662648 · Phase 3 · registry result, not featured evidence
-5.07 score @ 26wk
NCT01662648 · Phase 3 · registry result, not featured evidence
PANSS Total
absolute change · score
No placebo or comparator arm
-16.6 score @ 6wk160 mga,d,b,c
NCT01821378 · Phase 3 · registry result, not featured evidence
show 1 more dose
-8.9 score @ 6wk80 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
-12.3 score @ 6wka,d,b,c
NCT00535132 · Phase 4 · registry result, not featured evidence
show 1 more dose
-13.5 score @ 6wk
NCT00535132 · Phase 4 · registry result, not featured evidence
PANSS Total
absolute change · score
Extension (open-label)
No placebo or comparator arm
-28.4 score @ 32wk40-mg or 80-mgd,b,c,f
NCT01614912 · Phase 3 · registry result, not featured evidence
-26.4 score @ 52wkd,b,c,f
NCT01010776 · Phase 4 · registry result, not featured evidence
Dropout rate
32.8%40mgg
NCT00549718 · Phase 3 · monotherapy
show 42 more results
31.5%120mg
NCT00549718 · Phase 3 · monotherapy
30.1%80mg
NCT00549718 · Phase 3 · monotherapy
35.8%40 mg
NCT00615433 · Phase 3 · monotherapy
44.5%120 mg
NCT00615433 · Phase 3 · monotherapy
0%Lurasidone
NCT02199743 · Phase 4 · registry result, not featured evidence
—Lurasidone (LUR)
NCT02199743 · Phase 4 · registry result, not featured evidence
33.3%
NCT01569659 · Phase 4 · registry result, not featured evidence
11.1%40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
9.4%80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
14.4%
NCT02002832 · Phase 3 · registry result, not featured evidence
44%40-mg or 80-mg
NCT01614912 · Phase 3 · registry result, not featured evidence
29.3%40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
25.2%80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
26.7%20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
—80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
75.3%
NCT01485640 · Phase 3 · registry result, not featured evidence
18.8%
NCT01566162 · Phase 3 · registry result, not featured evidence
—
NCT01435928 · Phase 3 · registry result, not featured evidence
41.8%160 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
55.6%80 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
21.6%40/40
NCT01143077 · Phase 3 · registry result, not featured evidence
17%40/80
NCT01143077 · Phase 3 · registry result, not featured evidence
18.3%80/80
NCT01143077 · Phase 3 · registry result, not featured evidence
65.6%
NCT00641745 · Phase 3 · registry result, not featured evidence
23.1%160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
28.8%80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
33.6%40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
36.6%80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
22.2%flexible dose
NCT01731119 · Phase 2 · registry result, not featured evidence
88.5%80 mg
NCT00088621 · Phase 2 · registry result, not featured evidence
42.2%80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
42.4%40 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
66.7%80 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
59.4%20 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
62%20 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
59.4%40 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
56.3%80 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%80 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
10%40mg
NCT02174523 · Phase 1 · registry result, not featured evidence
14.3%
NCT01620060 · Phase 1 · registry result, not featured evidence
41.2%g
NCT00784238 · Phase 4 · registry result, not featured evidence
show 35 more results
48.4%
NCT00761579 · Phase 4 · registry result, not featured evidence
36.4%
NCT00761605 · Phase 4 · registry result, not featured evidence
20%
NCT01387542 · Phase 4 · registry result, not featured evidence
11.3%
NCT01362439 · Phase 4 · registry result, not featured evidence
—Paliperidone ER - Extension Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
—Paliperidone ER - Main Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
32.6%
NCT01724359 · Phase 4 · registry result, not featured evidence
27.1%
NCT01577186 · Phase 4 · registry result, not featured evidence
40.5%
NCT00757705 · Phase 4 · registry result, not featured evidence
27.8%
NCT01577160 · Phase 4 · registry result, not featured evidence
—Paliperidone ER Phase
NCT00535145 · Phase 4 · registry result, not featured evidence
25.4%Study Treatment
NCT00535145 · Phase 4 · registry result, not featured evidence
—TAU - Pali ER
NCT00535145 · Phase 4 · registry result, not featured evidence
40%6 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
47%1.5 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
0%PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
0%PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
—Paliperidone DB/Paliperidone Open-
NCT01662310 · Phase 3 · registry result, not featured evidence
—Paliperidone: Double Blind (DB) Ph
NCT01662310 · Phase 3 · registry result, not featured evidence
36.4%Paliperidone (Double-blind)/Palipe
NCT00488319 · Phase 3 · registry result, not featured evidence
50.2%Paliperidone (No Double-blind)/Pal
NCT00488319 · Phase 3 · registry result, not featured evidence
38.5%Placebo/Paliperidone
NCT00488319 · Phase 3 · registry result, not featured evidence
24.8%
NCT01009047 · Phase 3 · registry result, not featured evidence
19.1%
NCT01541371 · Phase 3 · registry result, not featured evidence
50%
NCT00473434 · Phase 3 · registry result, not featured evidence
20.4%
NCT00566631 · Phase 3 · registry result, not featured evidence
—
NCT00645099 · Phase 3 · registry result, not featured evidence
28.3%Paliperidone ER: Lack of Efficacy
NCT01662648 · Phase 3 · registry result, not featured evidence
29.8%Paliperidone ER: Lack of Tolerabil
NCT01662648 · Phase 3 · registry result, not featured evidence
22.9%Pali ER High
NCT00518323 · Phase 3 · registry result, not featured evidence
35.2%Pali ER Low
NCT00518323 · Phase 3 · registry result, not featured evidence
16.7%Pali ER Medium
NCT00518323 · Phase 3 · registry result, not featured evidence
15.4%
NCT01606228 · Phase 3 · registry result, not featured evidence
45.4%
NCT01561898 · Phase 3 · registry result, not featured evidence
35.3%
NCT00396565 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
4.8%40mgg
NCT00549718 · Phase 3 · monotherapy
show 42 more results
5.6%120mg
NCT00549718 · Phase 3 · monotherapy
6.5%80mg
NCT00549718 · Phase 3 · monotherapy
—40 mg
NCT00615433 · Phase 3 · monotherapy
—120 mg
NCT00615433 · Phase 3 · monotherapy
—Lurasidone
NCT02199743 · Phase 4 · registry result, not featured evidence
—Lurasidone (LUR)
NCT02199743 · Phase 4 · registry result, not featured evidence
—
NCT01569659 · Phase 4 · registry result, not featured evidence
4.6%40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
2.8%80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
—
NCT02002832 · Phase 3 · registry result, not featured evidence
—40-mg or 80-mg
NCT01614912 · Phase 3 · registry result, not featured evidence
—40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
—80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
—20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
—80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
6.2%
NCT01485640 · Phase 3 · registry result, not featured evidence
—
NCT01566162 · Phase 3 · registry result, not featured evidence
—
NCT01435928 · Phase 3 · registry result, not featured evidence
6.3%160 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
6.9%80 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
6.8%40/40
NCT01143077 · Phase 3 · registry result, not featured evidence
6.8%40/80
NCT01143077 · Phase 3 · registry result, not featured evidence
6.1%80/80
NCT01143077 · Phase 3 · registry result, not featured evidence
—
NCT00641745 · Phase 3 · registry result, not featured evidence
—160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
—80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
—40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
—80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
—flexible dose
NCT01731119 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00088621 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
—40 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
—20 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
—20 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
—40 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
—80 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
—40 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
—80 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
—20 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
—40mg
NCT02174523 · Phase 1 · registry result, not featured evidence
8.6%
NCT01620060 · Phase 1 · registry result, not featured evidence
4.8%g
NCT00784238 · Phase 4 · registry result, not featured evidence
show 35 more results
5.3%
NCT00761579 · Phase 4 · registry result, not featured evidence
6.7%
NCT00761605 · Phase 4 · registry result, not featured evidence
7.5%
NCT01387542 · Phase 4 · registry result, not featured evidence
0.8%
NCT01362439 · Phase 4 · registry result, not featured evidence
—Paliperidone ER - Extension Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
—Paliperidone ER - Main Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
10.5%
NCT01724359 · Phase 4 · registry result, not featured evidence
4.8%
NCT01577186 · Phase 4 · registry result, not featured evidence
6.4%
NCT00757705 · Phase 4 · registry result, not featured evidence
2.5%
NCT01577160 · Phase 4 · registry result, not featured evidence
—Paliperidone ER Phase
NCT00535145 · Phase 4 · registry result, not featured evidence
2.6%Study Treatment
NCT00535145 · Phase 4 · registry result, not featured evidence
—TAU - Pali ER
NCT00535145 · Phase 4 · registry result, not featured evidence
2.9%6 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
10.6%1.5 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
—PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
—PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
—Paliperidone DB/Paliperidone Open-
NCT01662310 · Phase 3 · registry result, not featured evidence
—Paliperidone: Double Blind (DB) Ph
NCT01662310 · Phase 3 · registry result, not featured evidence
1.7%Paliperidone (Double-blind)/Palipe
NCT00488319 · Phase 3 · registry result, not featured evidence
9.5%Paliperidone (No Double-blind)/Pal
NCT00488319 · Phase 3 · registry result, not featured evidence
2.6%Placebo/Paliperidone
NCT00488319 · Phase 3 · registry result, not featured evidence
4.4%
NCT01009047 · Phase 3 · registry result, not featured evidence
3.7%
NCT01541371 · Phase 3 · registry result, not featured evidence
4.7%
NCT00473434 · Phase 3 · registry result, not featured evidence
3.1%
NCT00566631 · Phase 3 · registry result, not featured evidence
—
NCT00645099 · Phase 3 · registry result, not featured evidence
8.3%Paliperidone ER: Lack of Efficacy
NCT01662648 · Phase 3 · registry result, not featured evidence
6.2%Paliperidone ER: Lack of Tolerabil
NCT01662648 · Phase 3 · registry result, not featured evidence
2.1%Pali ER High
NCT00518323 · Phase 3 · registry result, not featured evidence
1.9%Pali ER Low
NCT00518323 · Phase 3 · registry result, not featured evidence
2.1%Pali ER Medium
NCT00518323 · Phase 3 · registry result, not featured evidence
0.5%
NCT01606228 · Phase 3 · registry result, not featured evidence
14.4%
NCT01561898 · Phase 3 · registry result, not featured evidence
3.7%
NCT00396565 · Phase 3 · registry result, not featured evidence
Serious AEs
1.6%40mgg
NCT00549718 · Phase 3 · monotherapy
show 42 more results
4.8%120mg
NCT00549718 · Phase 3 · monotherapy
2.5%80mg
NCT00549718 · Phase 3 · monotherapy
1.7%40 mg
NCT00615433 · Phase 3 · monotherapy
5.1%120 mg
NCT00615433 · Phase 3 · monotherapy
—Lurasidone
NCT02199743 · Phase 4 · registry result, not featured evidence
7.1%Lurasidone (LUR)
NCT02199743 · Phase 4 · registry result, not featured evidence
3%
NCT01569659 · Phase 4 · registry result, not featured evidence
3.6%40 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
1.9%80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
0.5%
NCT02002832 · Phase 3 · registry result, not featured evidence
11%40-mg or 80-mg
NCT01614912 · Phase 3 · registry result, not featured evidence
2.7%40 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
1.9%80 mg
NCT01614899 · Phase 3 · registry result, not featured evidence
3%20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
3%80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
4.3%
NCT01485640 · Phase 3 · registry result, not featured evidence
6.8%
NCT01566162 · Phase 3 · registry result, not featured evidence
4.2%
NCT01435928 · Phase 3 · registry result, not featured evidence
7.6%160 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
12.5%80 mg
NCT00789698 · Phase 3 · registry result, not featured evidence
4.2%40/40
NCT01143077 · Phase 3 · registry result, not featured evidence
2.3%40/80
NCT01143077 · Phase 3 · registry result, not featured evidence
0%80/80
NCT01143077 · Phase 3 · registry result, not featured evidence
11%
NCT00641745 · Phase 3 · registry result, not featured evidence
3.3%160 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
0.8%80 mg
NCT00790192 · Phase 3 · registry result, not featured evidence
6.3%40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
5.3%80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
0%flexible dose
NCT01731119 · Phase 2 · registry result, not featured evidence
20.3%80 mg
NCT00088621 · Phase 2 · registry result, not featured evidence
2.2%80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
18.2%40 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
9.1%80 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
9.4%20 mg
NCT00044005 · Phase 2 · registry result, not featured evidence
5.6%20 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
13.4%40 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
4.2%80 mg
NCT00044044 · Phase 2 · registry result, not featured evidence
0%40 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%80 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%20 mg
NCT02174510 · Phase 1 · registry result, not featured evidence
0%40mg
NCT02174523 · Phase 1 · registry result, not featured evidence
1.9%
NCT01620060 · Phase 1 · registry result, not featured evidence
7.3%g
NCT00784238 · Phase 4 · registry result, not featured evidence
show 35 more results
12.1%
NCT00761579 · Phase 4 · registry result, not featured evidence
9.8%
NCT00761605 · Phase 4 · registry result, not featured evidence
2.5%
NCT01387542 · Phase 4 · registry result, not featured evidence
0.8%
NCT01362439 · Phase 4 · registry result, not featured evidence
1.9%Paliperidone ER - Extension Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
6.5%Paliperidone ER - Main Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
7.4%
NCT01724359 · Phase 4 · registry result, not featured evidence
7.7%
NCT01577186 · Phase 4 · registry result, not featured evidence
3.7%
NCT00757705 · Phase 4 · registry result, not featured evidence
0%
NCT01577160 · Phase 4 · registry result, not featured evidence
2.4%Paliperidone ER Phase
NCT00535145 · Phase 4 · registry result, not featured evidence
—Study Treatment
NCT00535145 · Phase 4 · registry result, not featured evidence
0%TAU - Pali ER
NCT00535145 · Phase 4 · registry result, not featured evidence
7.1%6 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
10.6%1.5 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
4%PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
3.1%PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
4.3%Paliperidone DB/Paliperidone Open-
NCT01662310 · Phase 3 · registry result, not featured evidence
3.1%Paliperidone: Double Blind (DB) Ph
NCT01662310 · Phase 3 · registry result, not featured evidence
3.4%Paliperidone (Double-blind)/Palipe
NCT00488319 · Phase 3 · registry result, not featured evidence
18.9%Paliperidone (No Double-blind)/Pal
NCT00488319 · Phase 3 · registry result, not featured evidence
23.1%Placebo/Paliperidone
NCT00488319 · Phase 3 · registry result, not featured evidence
6.2%
NCT01009047 · Phase 3 · registry result, not featured evidence
0.2%
NCT01541371 · Phase 3 · registry result, not featured evidence
42.2%
NCT00473434 · Phase 3 · registry result, not featured evidence
7.8%
NCT00566631 · Phase 3 · registry result, not featured evidence
8.8%
NCT00645099 · Phase 3 · registry result, not featured evidence
6.8%Paliperidone ER: Lack of Efficacy
NCT01662648 · Phase 3 · registry result, not featured evidence
4.9%Paliperidone ER: Lack of Tolerabil
NCT01662648 · Phase 3 · registry result, not featured evidence
2.1%Pali ER High
NCT00518323 · Phase 3 · registry result, not featured evidence
3.7%Pali ER Low
NCT00518323 · Phase 3 · registry result, not featured evidence
2.1%Pali ER Medium
NCT00518323 · Phase 3 · registry result, not featured evidence
2.1%
NCT01606228 · Phase 3 · registry result, not featured evidence
—
NCT01561898 · Phase 3 · registry result, not featured evidence
3%
NCT00396565 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
40mgg
headache 18.5% (placebo 15.7%)
akathisia 11.3% (placebo 51.2%)
nausea 11.3% (placebo 7.1%)
NCT00549718 · Phase 3 · monotherapy
show 41 more results
120mg
akathisia 24.2% (placebo 51.2%)
headache 16.9% (placebo 15.7%)
somnolence 14.5% (placebo 5.5%)
NCT00549718 · Phase 3 · monotherapy
80mg
akathisia 17.4% (placebo 51.2%)
headache 13.2% (placebo 15.7%)
sedation 10.7% (placebo 4.7%)
NCT00549718 · Phase 3 · monotherapy
40 mg
headache 21.8% (placebo 21.6%)
insomnia 12.6% (placebo 11.2%)
akathisia 11.8% (placebo 0.9%)
NCT00615433 · Phase 3 · monotherapy
120 mg
akathisia 22.9% (placebo 0.9%)
headache 17.8% (placebo 21.6%)
somnolence 15.3% (placebo 4.3%)
NCT00615433 · Phase 3 · monotherapy
insomnia 21.4%
sedation 21.4%
stiffness in jaw 14.3%
NCT02199743 · Phase 4 · registry result, not featured evidence
nausea 27.3%
headache 15.2%
insomnia 12.1%
NCT01569659 · Phase 4 · registry result, not featured evidence
40 mg
nausea 12.7% (placebo 2.7%)
anxiety 10% (placebo 8%)
akathisia 9.1% (placebo 1.8%)
NCT01911429 · Phase 3 · registry result, not featured evidence
80 mg
nausea 14.4% (placebo 2.7%)
somnolence 11.5% (placebo 5.4%)
headache 10.6% (placebo 12.5%)
NCT01911429 · Phase 3 · registry result, not featured evidence
extrapyramidal disorder 17%
consitpation 12.9%
insomnia 9.8%
NCT02002832 · Phase 3 · registry result, not featured evidence
40-mg or 80-mg
insomnia 11.3%
akathisia 11%
nasopharyngitis 10.6%
NCT01614912 · Phase 3 · registry result, not featured evidence
40 mg
headache 9.3% (placebo 7.9%)
constipation 8.7% (placebo 7.9%)
akathisia 7.3% (placebo 3.3%)
NCT01614899 · Phase 3 · registry result, not featured evidence
80 mg
akathisia 10.4% (placebo 3.3%)
nausea 7.8% (placebo 4.6%)
anxiety 7.1% (placebo 5.3%)
NCT01614899 · Phase 3 · registry result, not featured evidence
20 mg
insomnia 15.8% (placebo 21.4%)
headache 9.9% (placebo 7.1%)
anxiety 7.9% (placebo 6.3%)
NCT01821378 · Phase 3 · registry result, not featured evidence
80-160 mg
akathisia 10.6% (placebo 1.8%)
insomnia 10.6% (placebo 21.4%)
nausea 8.6% (placebo 3.6%)
NCT01821378 · Phase 3 · registry result, not featured evidence
headache 5.6%
diarrhoea 3.7%
influenza 3.7%
NCT01485640 · Phase 3 · registry result, not featured evidence
akathisia 5.2%
schizophrenia 4.2%
nasopharyngitis 2.6%
NCT01566162 · Phase 3 · registry result, not featured evidence
schizophrenia 6.9% (placebo 7.8%)
insomnia 6.3% (placebo 7.1%)
anxiety 4.2% (placebo 2.8%)
NCT01435928 · Phase 3 · registry result, not featured evidence
160 mg
headache 13.9%
akathisia 10.1%
insomnia 8.9%
NCT00789698 · Phase 3 · registry result, not featured evidence
80 mg
akathisia 15.3%
headache 6.9%
insomnia 6.9%
NCT00789698 · Phase 3 · registry result, not featured evidence
40/40
nausea 13.9%
headache 9.7%
somnolence 9.7%
NCT01143077 · Phase 3 · registry result, not featured evidence
40/80
insomnia 18.4%
akathisia 14.9%
headache 11.5%
NCT01143077 · Phase 3 · registry result, not featured evidence
80/80
nausea 18.5%
insomnia 14.8%
akathisia 13.6%
NCT01143077 · Phase 3 · registry result, not featured evidence
nausea 16.7%
insomnia 15.8%
sedation 14.6%
NCT00641745 · Phase 3 · registry result, not featured evidence
160 mg
headache 9.9% (placebo 10.7%)
akathisia 7.4% (placebo 0.8%)
vomiting 7.4% (placebo 5%)
NCT00790192 · Phase 3 · registry result, not featured evidence
80 mg
insomnia 11.2% (placebo 9.1%)
headache 9.6% (placebo 10.7%)
akathisia 8% (placebo 0.8%)
NCT00790192 · Phase 3 · registry result, not featured evidence
40 mg
insomnia 14.2% (placebo 14.4%)
schizophrenia 11.8% (placebo 18.9%)
nasopharyngitis 10.2% (placebo 9.8%)
NCT00711269 · Phase 3 · registry result, not featured evidence
80 mg
insomnia 19.1% (placebo 14.4%)
schizophrenia 19.1% (placebo 18.9%)
akathisia 11.5% (placebo 4.5%)
NCT00711269 · Phase 3 · registry result, not featured evidence
flexible dose
nausea 33.3%
NCT01731119 · Phase 2 · registry result, not featured evidence
80 mg
bronchitis 6.8%
nausea 6.8%
sedation 6.8%
NCT00088621 · Phase 2 · registry result, not featured evidence
80 mg
nausea 16.7% (placebo 3.3%)
constipation 11.1% (placebo 5.6%)
headache 11.1% (placebo 10%)
NCT00088634 · Phase 2 · registry result, not featured evidence
40 mg
dizziness 18.2%
headache 15.2%
nasopharyngitis 12.1%
NCT00044005 · Phase 2 · registry result, not featured evidence
80 mg
headache 15.2%
depression 12.1%
oropharyngeal pain 9.1%
NCT00044005 · Phase 2 · registry result, not featured evidence
20 mg
headache 15.6%
insomnia 9.4%
nasopharyngitis 9.4%
NCT00044005 · Phase 2 · registry result, not featured evidence
headache 21.1% (placebo 33.3%)
dyspepsia 11.3% (placebo 9.7%)
nausea 11.3% (placebo 11.1%)
NCT00044044 · Phase 2 · registry result, not featured evidence
headache 23.9% (placebo 33.3%)
sedation 16.4% (placebo 8.3%)
agitation 13.4% (placebo 4.2%)
NCT00044044 · Phase 2 · registry result, not featured evidence
headache 23.9% (placebo 33.3%)
sedation 21.1% (placebo 8.3%)
akathisia 18.3% (placebo 9.7%)
NCT00044044 · Phase 2 · registry result, not featured evidence
40 mg
somnolence 75% (placebo 33.3%)
blood prolactin increased 12.5% (placebo 22.2%)
irritability 12.5% (placebo 0%)
NCT02174510 · Phase 1 · registry result, not featured evidence
80 mg
somnolence 100% (placebo 33.3%)
blood prolactin increased 83.3% (placebo 22.2%)
dizziness 25% (placebo 0%)
NCT02174510 · Phase 1 · registry result, not featured evidence
20 mg
somnolence 62.5% (placebo 33.3%)
blood prolactin increased 12.5% (placebo 22.2%)
feeling hot 12.5% (placebo 0%)
NCT02174510 · Phase 1 · registry result, not featured evidence
40mg
somnolence 100% (placebo 0%)
blood prolactin increased 60% (placebo 25%)
restlessness 60% (placebo 0%)
NCT02174523 · Phase 1 · registry result, not featured evidence
somnelence 41.9%
sedation 18.1%
nausea 17.1%
NCT01620060 · Phase 1 · registry result, not featured evidence
g
akathisia 8.3%
extrapyramidal disorder 4.8%
insomnia 4.8%
NCT00784238 · Phase 4 · registry result, not featured evidence
show 33 more results
akathisia 18.4%
weight increased 15.3%
muscle rigidity 7.4%
NCT00761579 · Phase 4 · registry result, not featured evidence
insomnia 12.4%
akathisia 11.4%
weight increased 9.3%
NCT00761605 · Phase 4 · registry result, not featured evidence
drowsiness 15%
headache 15%
insomnia 12.5%
NCT01387542 · Phase 4 · registry result, not featured evidence
insomnia 3%
weight increase 3%
extrapyramidal symptoms 2.3%
NCT01362439 · Phase 4 · registry result, not featured evidence
weight increased 12.6%
insomnia 8.8%
depression 4.4%
NCT01010776 · Phase 4 · registry result, not featured evidence
insomnia 14.9%
anxiety 10.7%
weight increased 10.7%
NCT01010776 · Phase 4 · registry result, not featured evidence
insomnia 25.3%
akathisia 23.2%
parkinsonism 15.8%
NCT01724359 · Phase 4 · registry result, not featured evidence
extrapyramidal disorder 11.7%
upper respiratory tract infection 6.7%
tremor 4.8%
NCT01577186 · Phase 4 · registry result, not featured evidence
insomnia 20.7%
extrapyramidal disorder 13.7%
anxiety 11.7%
NCT00757705 · Phase 4 · registry result, not featured evidence
insomnia 15.9%
constipation 11.3%
extrapyramidal disorder 9.6%
NCT01577160 · Phase 4 · registry result, not featured evidence
tremor 8.3%
headache 7.1%
nausea 6%
NCT00535145 · Phase 4 · registry result, not featured evidence
weight increased 6%
headache 3.6%
akathisia 2.4%
NCT00535145 · Phase 4 · registry result, not featured evidence
6 mg
headache 11.4% (placebo 15.6%)
insomnia 10% (placebo 9.4%)
tremor 10% (placebo 3.1%)
NCT00524043 · Phase 4 · registry result, not featured evidence
1.5 mg
insomnia 13.6% (placebo 9.4%)
dizziness 7.6% (placebo 1.6%)
headache 7.6% (placebo 15.6%)
NCT00524043 · Phase 4 · registry result, not featured evidence
constipation 9.1%
insomnia 9.1%
somnolence 8.1%
NCT00535132 · Phase 4 · registry result, not featured evidence
insomnia 9.2%
headache 8.2%
constipation 6.1%
NCT00535132 · Phase 4 · registry result, not featured evidence
constipation 4.3% (placebo 3.4%)
akathisia 2.1% (placebo 5.1%)
headache 2.1% (placebo 1.7%)
NCT01662310 · Phase 3 · registry result, not featured evidence
akathisia 4.7% (placebo 5.1%)
nausea 3.1% (placebo 0%)
tremor 3.1% (placebo 0%)
NCT01662310 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.3%
somnolence 15.3%
tremor 10.2%
NCT00488319 · Phase 3 · registry result, not featured evidence
weight increased 24.3%
headache 18.9%
somnolence 18.5%
NCT00488319 · Phase 3 · registry result, not featured evidence
somnolence 25.6%
insomnia 17.9%
anxiety 10.3%
NCT00488319 · Phase 3 · registry result, not featured evidence
akathisia 11.5%
headache 10.6%
somnolence 10.6%
NCT01009047 · Phase 3 · registry result, not featured evidence
akathisia 18.4%
tremor 12.9%
dystonia 8.7%
NCT01541371 · Phase 3 · registry result, not featured evidence
insomnia 15.6%
headache 10.9%
akathisia 9.4%
NCT00473434 · Phase 3 · registry result, not featured evidence
insomnia 23.1%
tachycardia 8.5%
headache 7.5%
NCT00566631 · Phase 3 · registry result, not featured evidence
insomnia 9.6%
weight increased 9.6%
headache 4.6%
NCT00645099 · Phase 3 · registry result, not featured evidence
insomnia 9.8%
extrapyramidal disorder 6.6%
headache 4.5%
NCT01662648 · Phase 3 · registry result, not featured evidence
insomnia 11.6%
headache 4.1%
nausea 3.9%
NCT01662648 · Phase 3 · registry result, not featured evidence
somnolence 20.8% (placebo 2%)
akathisia 16.7% (placebo 0%)
insomnia 12.5% (placebo 21.6%)
NCT00518323 · Phase 3 · registry result, not featured evidence
headache 9.3% (placebo 3.9%)
insomnia 9.3% (placebo 21.6%)
schizophrenia 9.3% (placebo 7.8%)
NCT00518323 · Phase 3 · registry result, not featured evidence
somnolence 14.6% (placebo 2%)
akathisia 8.3% (placebo 0%)
tremor 8.3% (placebo 0%)
NCT00518323 · Phase 3 · registry result, not featured evidence
insomnia 13.3%
anemia 4.8%
acute psychotic symptoms 1.6%
NCT01606228 · Phase 3 · registry result, not featured evidence
schizophrenia 16.4% (placebo 42.8%)
insomnia 11.2% (placebo 10.1%)
nasopharyngitis 10.4% (placebo 8%)
NCT00396565 · Phase 3 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dTrial phases differ: Phase 3 versus Phase 4.
  5. eAssessment timepoints differ: 24 weeks versus 26 weeks.
  6. fAssessment timepoints differ: 32 weeks versus 52 weeks.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Lurasidone

BACS Composite -2.002433521 score @ 4wk
absolute change · score
No placebo or comparator arm
NCT02199743 · Phase 4 · registry result, not featured evidence
PANSS Positive -6.3 vs -3.1 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 3 more results
-2 vs -0.6 placebo score @ 6wk40 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
-6.3 vs -3.1 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
-1.4 vs -0.6 placebo score @ 6wk80 mg
NCT00711269 · Phase 3 · registry result, not featured evidence
PANSS 20 63.9% (n=108) vs 61.6% (n=112) placebo @ 6wk40 mg
responder rate · % of participants
NCT01911429 · Phase 3 · registry result, not featured evidence · converted to % from 69 number of participants as posted
show 3 more results
44.3% (n=106) vs 61.6% (n=112) placebo @ 6wk*80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence · converted to % from 47 number of participants as posted
44% (n=101) vs 73% (n=112) placebo @ 6wk20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
53% (n=198) vs 73% (n=112) placebo @ 6wk80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
PQLES Total 5.6 vs 0.3 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 1 more result
6.1 vs 0.3 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
PANSS Marder Uncontrolled Hostility/Excitement -0.6 vs -2.4 placebo score @ 6wk40 mg
absolute change · score
NCT01911429 · Phase 3 · registry result, not featured evidence
show 1 more result
-1.7 vs -2.4 placebo score @ 6wk80 mg
NCT01911429 · Phase 3 · registry result, not featured evidence
CGI-I 2 vs 1.9 Risperidone score @ 6wk
absolute value · score
NCT02002832 · Phase 3 · registry result, not featured evidence
CGI-S -1.46 score @ 32wk40-mg or 80-mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01614912 · Phase 3 · registry result, not featured evidence
show 1 more result
-0.48 score @ 12wk
NCT01566162 · Phase 3 · registry result, not featured evidence
PANSS Positive Subscale -8.4 score @ 32wk40-mg or 80-mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01614912 · Phase 3 · registry result, not featured evidence
PANSS Negative Subscale -6.9 score @ 32wk40-mg or 80-mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01614912 · Phase 3 · registry result, not featured evidence
PANSS General Psychopathology -13.1 score @ 32wk40-mg or 80-mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01614912 · Phase 3 · registry result, not featured evidence
MADRS -3.5 vs -1.7 placebo score @ 6wk160 mg
absolute change · score
NCT01821378 · Phase 3 · registry result, not featured evidence
show 8 more results
-2.5 vs -1.7 placebo score @ 6wk80 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
-2.9 vs -0.1 placebo score @ 6wk80 mg
NCT00088634 · Phase 2 · registry result, not featured evidence
-2 vs -1.7 placebo score @ 6wk20 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
-3.7 vs -1.7 placebo score @ 6wk80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence
2.5 vs 3.6 placebo score @ 28wk
NCT01435928 · Phase 3 · registry result, not featured evidence
-1.3 vs -1.9 placebo score @ 6wk
NCT00044044 · Phase 2 · registry result, not featured evidence
-1.1 vs -1.9 placebo score @ 6wk
NCT00044044 · Phase 2 · registry result, not featured evidence
-2.5 vs -1.9 placebo score @ 6wk
NCT00044044 · Phase 2 · registry result, not featured evidence
GAF 11.5 vs 9.2 placebo score @ 6wk20 mg
absolute change · score
NCT01821378 · Phase 3 · registry result, not featured evidence
show 1 more result
15.8 vs 9.2 placebo score @ 6wk80-160 mg
NCT01821378 · Phase 3 · registry result, not featured evidence

+ 10 further endpoints in the CSV export.

Paliperidone (Invega)

SWN-K Total 77.89 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Total -1.59 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-2.66 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-0.93 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Mental Functioning -0.14 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.51 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-0.24 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Self Control -0.72 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.62 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-0.29 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Emotional Regulation -0.07 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
0.11 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
0.45 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Physical Functioning -0.11 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.68 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
0.47 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Social Integration -0.55 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.96 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-1.31 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
DAI-10 Total 3.58 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
DAI-10 Total -0.46 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 3 more results
-0.21 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-1 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
1 score @ 12wk
NCT01577160 · Phase 4 · registry result, not featured evidence
SCL90-R 2.42 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
9.4 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
1.16 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
Krawiecka 0.94 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
1.09 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
1.09 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
PSP -6.5 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 25 more results
-7.23 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-6.28 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-4.289 score @ 2wk
NCT01387542 · Phase 4 · registry result, not featured evidence
-7.053 score @ 6wk
NCT01387542 · Phase 4 · registry result, not featured evidence
-9.868 score @ 10wk
NCT01387542 · Phase 4 · registry result, not featured evidence
59.44 score @ 4wk
NCT00761189 · Phase 4 · registry result, not featured evidence
62.76 score @ 12wk
NCT00761189 · Phase 4 · registry result, not featured evidence
60.27 score @ 4wk
NCT00761189 · Phase 4 · registry result, not featured evidence
64.73 score @ 12wk
NCT00761189 · Phase 4 · registry result, not featured evidence
9.05 score @ 13wk
NCT01362439 · Phase 4 · registry result, not featured evidence
5.7 score @ 4wk
NCT01010776 · Phase 4 · registry result, not featured evidence
8.3 score @ 8wk
NCT01010776 · Phase 4 · registry result, not featured evidence
9.9 score @ 13wk
NCT01010776 · Phase 4 · registry result, not featured evidence
10.4 score @ 26wk
NCT01010776 · Phase 4 · registry result, not featured evidence
68.24 score @ 26wk
NCT01724359 · Phase 4 · registry result, not featured evidence
9.05 score @ 12wk
NCT01577186 · Phase 4 · registry result, not featured evidence
3.4 score @ 24wk
NCT00757705 · Phase 4 · registry result, not featured evidence
14.3 score @ 12wk
NCT01577160 · Phase 4 · registry result, not featured evidence
2.8 score @ 8.86wk
NCT00535145 · Phase 4 · registry result, not featured evidence
6.3 score @ 1wk
NCT00566631 · Phase 3 · registry result, not featured evidence
9.9 score @ 2wk
NCT00566631 · Phase 3 · registry result, not featured evidence
13.8 score @ 4wk
NCT00566631 · Phase 3 · registry result, not featured evidence
16.1 score @ 6wk
NCT00566631 · Phase 3 · registry result, not featured evidence
13.76 score @ 26wk
NCT01662648 · Phase 3 · registry result, not featured evidence
11.14 score @ 26wk
NCT01662648 · Phase 3 · registry result, not featured evidence

+ 59 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lurasidone's landscape · Paliperidone (Invega)'s landscape